• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.79% Nasdaq Up0.53%

    Heat Biologics, Inc. (HTBX)

    6.22 Up 0.22(3.67%) Jul 1, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Heat Biologics, Inc.
    801 Capitola Drive
    Bay 12
    Durham, NC 27713
    United States - Map
    Phone: 919-240-7133
    Website: http://www.heatbio.com

    Index Membership:N/A
    Full Time Employees:14

    Business Summary 

    Heat Biologics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. Its Immune Pan-Antigen Cytotoxic Therapy platform technology is designed to educate and stimulate the immune system to combat cancer disease. The company’s products under development include therapeutic vaccine candidates, such as viagenpumatucel-L (HS-110) that is in Phase II clinical trials for the treatment of non-small cell lung cancer; and vesigenurtacel-L (HS-410), which is in Phase II clinical trials for the treatment of non-muscle invasive bladder cancer. It is also developing cell lines for the treatment of ovarian cancer, triple negative breast cancer, and pediatric rhabdomyosarcoma. The company was founded in 2008 and is headquartered in Durham, North Carolina.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Heat Biologics, Inc.

    Key Executives 
    Mr. Jeffrey Alan Wolf J.D., 52
    Founder, Chairman, Chief Exec. Officer, Pres, Treasurer and Sec.
    Dr. Anil K. Goyal Ph.D., 51
    VP of Bus. Devel.
    Dr. Melissa Price Ph.D., 41
    VP of Clinical & Regulatory Affairs
    Dr. Taylor H. Schreiber M.D., Ph.D., 35
    VP of R&D
    Mr. Stephen J. DiPalma M.B.A, 56
    Interim Chief Financial Officer
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders